Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28891327 | 0.88 | — | — | |
| SCHEMBL6408324 | 0.81 | — | — | |
| SCHEMBL2897093 | 0.79 | — | — | |
| SCHEMBL18281481 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL31141036 | 0.78 | EPHX1 (0.34) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL31404652 | 0.78 | EPHX1 (0.34) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL2899496 | 0.78 | EPHX1 (0.34) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8965920 | 0.78 | — | — | |
| SCHEMBL12960406 | 0.77 | — | — | |
| SCHEMBL10306106 | 0.77 | CYP4F2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | SLC6A2 1235/4885SLC6A3 1311/4885SLC6A4 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.